Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease

Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of pediatrics Vol. 214; pp. 227 - 230
Main Authors Oda, Takuya, Nagata, Hazumu, Nakashima, Yasutaka, Nanishi, Etsuro, Takada, Yui, Nishimura, Manao, Kubo, Eiji, Hatae, Ken, Ohga, Shouichi
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.11.2019
Subjects
Child, Preschool
concentration
Dose-Response Relationship, Drug
Female
fever duration
Follow-Up Studies
Humans
Immunoglobulins, Intravenous - administration & dosage
Immunologic Factors - administration & dosage
Infusions, Intravenous - statistics & numerical data
intravenous immunoglobulin
Male
Mucocutaneous Lymph Node Syndrome - drug therapy
preparation
Retrospective Studies
Treatment Outcome
treatment-related adverse event
CAA
fever duration
TEE
IVIG
concentration
treatment-related adverse event
intravenous immunoglobulin
preparation
Online AccessGet full text
ISSN0022-3476
1097-6833
1097-6833
DOI10.1016/j.jpeds.2019.06.018

Cover

More Information
Summary:Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0022-3476
1097-6833
1097-6833
DOI:10.1016/j.jpeds.2019.06.018